Pharmaceutical - Lyxumia

Filter

Current filters:

Lyxumia

Popular Filters

Sanofi’s Lyxumia meets primary endpoint in Ph IIIb diabetes study

Sanofi’s Lyxumia meets primary endpoint in Ph IIIb diabetes study

05-12-2013

Results of a 24-week Phase IIIb clinical study showed that French drug major Sanofi’s diabetes drug…

DiabetesLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Lyxumia plus basal insulin lowers blood sugar, latest data show

Lyxumia plus basal insulin lowers blood sugar, latest data show

05-10-2013

Sanofi has announced new GetGoal-L sub-analysis results showing that reductions in HbA1c with Lyxumia…

DiabetesLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Sanofi temporarily pulls lixisenatide NDA in USA

12-09-2013

French drug major Sanofi (Euronext: SAN) this morning (September 12) announced its decision to withdraw…

DiabeteslixisenatideLyxumiaNorth AmericaPharmaceuticalRegulationSanofiZealand Pharma

Sanofi's once-daily diabetes drug Lyxumia approved in Europe

04-02-2013

French drug major Sanofi (Euronext: SAN) this morning announced that the European Commission has granted…

DiabetesEuropeLyxumiaPharmaceuticalRegulationSanofi

Positive CHMP recommendations for Sanofi and Novartis, but not for Celgene

19-11-2012

There was a batch of good news for two pharma companies and a negative opinion for one last Friday coming…

BexseroBiotechnologyCelgeneDiabetesEuropeIstodaxLyxumiaNovartisOncologyPharmaceuticalRegulationSanofiVaccinesZaltrap

Sanofi files for Japanese approval of diabetes drug Lyxumia

11-06-2012

French drug major Sanofi (Euronext: SAN), has submitted a marketing authorization application for lixisenatide…

Asia-PacificDiabeteslixisenatideLyxumiaPharmaceuticalRegulationSanofiZealand Pharma

Highlights of American Diabetes Association meeting

11-06-2012

The weekend saw a flood of new data on diabetes drug candidates and currently approved treatments presented…

Boehringer IngelheimDegludecDiabetesEli LillyempagliflozinLyxumiaNovo NordiskPharmaceuticalResearchSanofiTradjentaVictoza

$20 million lixisenatide milestone for Zealand Pharma

13-02-2012

Danish peptide drug discovery firm Zealand Pharma (Nasdaq OMX Copenhagen: ZEAL) says it will receive…

DiabetesFinanciallixisenatideLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Sanofi files for EU approval of Lyxumia, a type-2 diabetes agent partnered with Zealand Pharma

04-11-2011

Danish drug discovery firm Zealand Pharma (Nasdaq OMX: ZEAL.CO), says that its partner, French drug major…

DiabetesFinancialLyxumiaPharmaceuticalRegulationSanofiZealand Pharma

Sanofi presents positive results with Lyxumia and Lantus in type 2 diabetes at EASD meeting

13-09-2011

French drug major Sanofi (Euronext: SAN) has reported positive results from the GetGoal-F1 study with…

DiabetesLantusLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Back to top